Agilent Technologies presents Thought Leader Award to renowned medicinal scientist in China
Dr Shilin Chen Recognized for Herbal Genomics Research.
Agilent Technologies has announced that Dr Shilin Chen has received an Agilent Thought Leader Award in support of his ground-breaking herbal genomics research using multi-omics techniques.
Dr Chen directs the Institute of Chinese Materia Medica at the China Academy of Chinese Medical Sciences in Beijing. The institute strives to identify the active ingredients in traditional Chinese medicines and make new drugs.
The award will fund the use of integrated biology — including various multi-omic solutions from Agilent — to generate important biological data sets related to the biosynthesis of bioactive compounds from herbs, including artemisinin and glycyrrhizin, for example.
Through his research, Dr Chen hopes to deepen understanding of the mechanism by which herbal medicines disrupt diseases and identify relevant biomarkers, which could then point the way to new drug discovery.
“We are delighted to receive an Agilent Thought Leader Award. It will allow us to incorporate integrated experimental and bioinformatics approaches to traditional Chinese medicine,” said Dr Chen. “Our group is focusing on dissecting and understanding the biosynthesis and regulatory mechanisms responsible for specific metabolic processes generated by natural herbs. We have initiated the herbal genomic project, and Agilent’s innovative technologies and unique solutions can provide new tools and approaches to help us combine metabolomics and genomics in the study of traditional Chinese medicine. We are looking forward to working collaboratively with Agilent scientists to accelerate the discovery and characterization of new medicines.”
“We are pleased to support Dr Chen’s efforts in the systems-level analysis of herbal metabolic processes using integrated omics approaches,” said Dr Teng Chai Hock, vice president and general manager of Agilent’s Life Sciences and Applied Markets Group in Greater China. “Dr Chen’s research is a prime example of continued innovation in traditional Chinese medicine through the application of advanced analytical methods.”
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance